Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 282 matching drugs for MET — including drugs targeting any of its 38 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
sunitinib MET Direct 5
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MET Direct 3
crizotinib MET Direct yes 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel MET Direct 2
cabozantinib MET Direct yes 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib MET Direct 2
tivantinib MET Direct 2
amivantamab MET Direct 1
atezolizumab, cabozantinib MET Direct 1
atezolizumab, tivozanib MET Direct 1
biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib MET Direct 1
biopsy, biospecimen collection, crizotinib, radiologic examination MET Direct 1
cabozantinib, durvalumab, tremelimumab MET Direct 1
cabozantinib, nivolumab MET Direct 1
cabozantinib, pembrolizumab MET Direct 1
gemcitabine, sunitinib MET Direct 1
ko-2806, cabozantinib, adagrasib MET Direct 1
laboratory biomarker analysis, pegfilgrastim, pharmacological study, tivantinib, topotecan hydrochloride MET Direct 1
nivolumab, cabozantinib MET Direct 1
ryz101, everolimus, sunitinib, octreotide, lanreotide MET Direct 1
sunitinib, placebo MET Direct 1
sunitinib, radiation MET Direct 1
sunitinib, sunitinib MET Direct 1
tivantinib, folfox MET Direct 1
tivozanib MET Direct 1
cabozantinib s-malate MET Direct yes 0
capmatinib MET Direct yes 0
capmatinib hydrochloride MET Direct yes 0
tepotinib MET Direct yes 0
sunitinib KIT SSL via KIT yes 5
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab KIT SSL via KIT 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab NTRK1 SSL via NTRK1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) KIT SSL via KIT 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) NTRK1 SSL via NTRK1 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB2 SSL via ERBB2 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB4 SSL via ERBB4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib KIT SSL via KIT 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib NTRK1 SSL via NTRK1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMO SSL via SMO 3
afatinib ERBB2 SSL via ERBB2 yes 3
afatinib ERBB4 SSL via ERBB4 yes 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB2 SSL via ERBB2 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB4 SSL via ERBB4 3
pembrolizumab, belzutifan, lenvatinib KIT SSL via KIT 3
trastuzumab emtansine ERBB2 SSL via ERBB2 yes 3
tucatinib ERBB2 SSL via ERBB2 yes 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB2 SSL via ERBB2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB4 SSL via ERBB4 2
avapritinib KIT SSL via KIT yes 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment KIT SSL via KIT 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab ERBB2 SSL via ERBB2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib ERBB2 SSL via ERBB2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib NTRK1 SSL via NTRK1 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC2 SSL via HDAC2 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a KIT SSL via KIT 2
lapatinib ERBB2 SSL via ERBB2 yes 2
lenvatinib, pembrolizumab KIT SSL via KIT 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate KIT SSL via KIT 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a KIT SSL via KIT 2
motexafin gadolinium, radiation therapy RRM2 SSL via RRM2 2
pazopanib KIT SSL via KIT yes 2
pembrolizumab, guadecitabine, mocetinostat HDAC2 SSL via HDAC2 2
pembrolizumab, lenvatinib KIT SSL via KIT 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu KIT SSL via KIT 2
pembrolizumab, sonidegib SMO SSL via SMO 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin KIT SSL via KIT 2
pharmacological study, romidepsin HDAC2 SSL via HDAC2 2
radiotherapy targeted to the primary lesion, radiotherapy targeted to the metastatic lesions, anti-pd-1 monoclonal antibody, trastuzumab, chemotherapy, r0 total/subtotal gastrectomy with d2 lymphadenectomy, metastasectomy, local ablative therapies ERBB2 SSL via ERBB2 2
regorafenib KIT SSL via KIT yes 2
regorafenib NTRK1 SSL via NTRK1 2
regorafenib, laboratory biomarker analysis KIT SSL via KIT 2
regorafenib, laboratory biomarker analysis NTRK1 SSL via NTRK1 2
sorafenib, administered orally, ct/mri KIT SSL via KIT 2
trastuzumab ERBB2 SSL via ERBB2 yes 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy ERBB2 SSL via ERBB2 2
trastuzumab, tipifarnib ERBB2 SSL via ERBB2 2
2b3-101, trastuzumab, 2b3-101 60 mg/m2 every 4 weeks, 2b3-101 50 mg/m2 every 3 weeks ERBB2 SSL via ERBB2 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat HDAC2 SSL via HDAC2 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat HDAC2 SSL via HDAC2 1
3-dimensional conformal radiation therapy, motexafin gadolinium, temozolomide RRM2 SSL via RRM2 1
5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy ERBB2 SSL via ERBB2 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy HDAC2 SSL via HDAC2 1
adriamycin, cyclophosphamide, vindesine, valproic acid HDAC2 SSL via HDAC2 1
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging ERBB2 SSL via ERBB2 1
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging ERBB4 SSL via ERBB4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ERBB2 SSL via ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ERBB4 SSL via ERBB4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib KIT SSL via KIT 1
afatinib, docetaxel, radiation therapy ERBB2 SSL via ERBB2 1
afatinib, docetaxel, radiation therapy ERBB4 SSL via ERBB4 1
afatinib, gefitinib ERBB2 SSL via ERBB2 1
afatinib, gefitinib ERBB4 SSL via ERBB4 1
afatinib, irinotecan ERBB2 SSL via ERBB2 1
afatinib, irinotecan ERBB4 SSL via ERBB4 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib SMO SSL via SMO 1
atezolizumab, tivozanib KIT SSL via KIT 1
atorvastatin, temozolomide, radiotherapy AHR SSL via AHR 1
atorvastatin, temozolomide, radiotherapy HDAC2 SSL via HDAC2 1
avapritinib, midazolam KIT SSL via KIT 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab HDAC2 SSL via HDAC2 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.